文献速递结核与非结核分枝杆菌

成人潜伏性结核感染每日利福平或异烟肼治疗的不良事件:两项随机对照试验的事后安全性分析

Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
PubMed 文献 · Lancet Infect Dis · 2019-12-19

该事后安全性分析合并两项开放标签随机对照试验,比较成人潜伏性结核感染每日利福平(4个月,10 mg/kg)与异烟肼(9个月,5 mg/kg)的不良事件。

要点

  • 利福平不良事件与依从性不一致及合并用药相关,与年龄无关。

核心结论

  • 在无禁忌证的患者中,利福平可能是最安全的潜伏性结核感染治疗方案。
  • 利福平安全性优于异烟肼且不良事件与高龄无关,应成为潜伏性结核感染的主要治疗选择。
  • 利福平更广泛使用后可能观察到罕见但严重的不良事件。

研究设计与样本

  • 基于两项开放标签随机对照试验的事后安全性分析,试验在澳大利亚、贝宁、巴西、加拿大、加纳、几内亚、印度尼西亚、沙特阿拉伯和韩国开展。
  • 纳入年龄≥18岁、潜伏性结核感染诊断试验阳性且有治疗指征、无利福平或异烟肼禁忌证的成人。
  • 患者按1:1随机接受4个月每日利福平10 mg/kg或9个月每日异烟肼5 mg/kg。
  • 安全性人群为异烟肼组3205例和利福平组3280例。
  • 主要结局为经设盲独立三人裁定委员会判定可能或很可能与研究药物相关、导致永久停药的不良事件(包括1–2级皮疹和所有3–5级事件)。

主要发现

  • 异烟肼组发生1例治疗相关死亡。

临床怎么用

  • 对无利福平禁忌证的潜伏性结核感染成人,可优先考虑每日利福平方案以降低不良事件导致停药的风险。
  • 使用异烟肼时,应关注年龄相关的不良事件风险,尤其是35岁以上成人。
  • 使用利福平时,应评估并管理服药依从性和合并用药以降低不良事件风险。

局限性

  • 为事后安全性分析,非预设主要安全性终点。
  • 两项试验为开放标签设计。
  • 安全性人群来自特定国家/地区的医疗设施,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An important problem limiting treatment of latent tuberculosis infection is the occurrence of adverse events with isoniazid. We combined populations from phase 2 and phase 3 open-label, randomised controlled trials, to establish risk factors for adverse events during latent tuberculosis infection treatment. METHODS: We did a post-hoc safety analysis based on data from two open-label, randomised controlled trials done in health-care facilities in Australia, Benin, Brazil, Canada, Ghana, Guinea, Indonesia, Saudi Arabia, and South Korea. Participants were consenting adults (aged ≥18 years) with a positive latent tuberculosis infection diagnostic test, indication for treatment, and without contraindications to rifampicin or isoniazid. Patients were centrally randomly assigned 1:1 to 4 months of daily 10 mg/kg rifampicin or 9 months of daily 5 mg/kg isoniazid. The primary outcome evaluated was adverse events (including grade 1-2 rash and all events of grade 3-5) resulting in permanent discontinuation of study medication and judged possibly or probably related to study drug by a masked, independent, three-member adjudication panel (trial registration: NCT00170209; NCT00931736). FINDINGS: Participants were recruited from April 27, 2004, up until Jan 31, 2007 (phase 2), and Oct 1, 2009, up until Dec 31, 2014 (phase 3). The safety populations for each group comprised 3205 individuals receiving isoniazid and 3280 receiving rifampicin. Among those receiving isoniazid, 86 (2·7%) of 3205 had grade 1-2 rash or any grade 3-5 adverse events, more than the 50 (1·5%) of 3280 who had these events with rifampicin (risk difference -1·2%, 95% CI -1·9 to -0·5). Age was associated with adverse events in adults receiving isoniazid. Compared with individuals aged 18-34 years, the adjusted odds ratio (OR) for adverse events was 1·8 (95% CI 1·1-3·0) for individuals aged 35-64 years and 3·0 (1·2-6·8) for individuals aged 65-90 years. With rifampicin, adverse events were associated with inconsistent medication adherence (adjusted OR 2·0, 1·1-3·6) and concomitant medication use (2·8, 1·5-5·2), but not age, with an adjusted OR of 1·1 (0·6-2·1) for individuals aged 35-64 years and 1·7 (0·5-4·7) for individuals aged 65-90 years. One treatment-related death occurred in the isoniazid group. INTERPRETATION: In patients without a contraindication, rifampicin is likely to be the safest latent tuberculosis infection treatment option. With more widespread use of rifampicin, rare, but serious adverse events might be seen. However, within these randomised trials, rifampicin was safer than isoniazid and adverse events were not associated with older age. Therefore, rifampicin should become a primary treatment option for latent tuberculosis infection based on its safety. FUNDING: Canadian Institutes of Health Research.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Campbell JR, Trajman A, Cook VJ, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2019. PMID: 31866327. doi:10.1016/S1473-3099(19)30575-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。